RPRX

Royalty Pharma plc NASDAQ

Healthcare ·Biotechnology ·US · royaltypharma.com

$49.47

Mkt Cap $27.7B

52w Low $31.97 94.6% of range 52w High $50.47

50d MA $47.15 200d MA $40.41

P/E (TTM) 21.2x

EV/EBITDA 15.3x

P/B 2.2x

Debt/Equity 1.4x

ROE 20.4%

P/FCF 6.7x

RSI (14) —

ATR (14) —

Beta 0.39

50d MA $47.15

200d MA $40.41

Avg Volume 3.4M

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 11, 2026	AMC	1.29	1.46	+13.2%	44.25	-0.0%	+1.2%	+2.1%	+2.6%	+2.5%	+1.9%	+3.2%	—
Nov 5, 2025	AMC	0.99	1.17	+17.7%	40.42	+0.6%	+0.9%	-4.6%	-4.7%	-3.6%	-2.1%	-1.7%	—
Aug 6, 2025	AMC	1.03	1.14	+10.7%	37.12	+0.0%	-0.3%	+1.2%	-2.5%	-3.4%	-1.8%	-2.8%	—
May 8, 2025	AMC	0.95	1.06	+11.2%	33.10	+0.4%	+0.2%	+0.8%	-0.8%	-2.4%	+0.1%	+0.9%	—
Feb 11, 2025	AMC	0.99	1.15	+16.2%	32.25	+0.1%	+0.3%	+0.7%	+0.3%	+1.9%	+1.1%	+1.3%	—
Nov 6, 2024	AMC	0.93	1.04	+12.1%	26.64	+1.4%	-0.5%	-1.6%	-1.1%	-2.4%	-3.0%	-2.7%	—
Aug 8, 2024	AMC	0.96	0.96	-0.5%	26.15	+0.7%	+0.4%	+1.1%	+2.7%	+1.9%	+4.8%	+7.5%	—
May 9, 2024	AMC	0.99	0.98	-0.7%	27.97	+1.9%	+0.4%	+1.5%	+0.4%	+0.9%	-0.3%	-2.1%	—
Feb 15, 2024	AMC	1.01	1.15	+13.9%	30.03	+0.0%	-0.4%	+0.9%	+4.0%	+3.3%	+3.3%	+0.1%	—
Nov 8, 2023	AMC	0.81	0.79	-2.5%	27.62	+0.9%	-0.8%	-1.4%	-1.8%	-0.4%	-2.2%	+3.4%	—
Aug 8, 2023	AMC	0.83	0.85	+2.4%	30.55	+0.6%	+0.0%	+0.1%	-0.3%	-1.4%	-2.5%	-5.5%	—
May 9, 2023	AMC	1.32	1.60	+21.2%	33.99	-0.1%	-0.4%	+1.5%	+1.6%	+1.0%	-2.2%	+1.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 21	UBS	Maintains	Buy → Buy	—	$49.30	$49.59	+0.6%	+0.4%	+0.9%	+0.7%	+0.2%	+0.7%
Apr 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$48.30	$48.30	+0.0%	-0.8%	+0.3%	+1.1%	+0.8%	+0.4%
Jan 30	UBS	Upgrade	Neutral → Buy	—	$40.86	$41.27	+1.0%	+2.0%	+3.7%	+5.2%	+6.9%	+7.9%
Jan 27	Citigroup	Maintains	Buy → Buy	—	$40.47	$40.50	+0.1%	+0.7%	-0.1%	+1.0%	+3.0%	+4.7%
Dec 11	TD Cowen	Maintains	Buy → Buy	—	$38.26	$38.30	+0.1%	+1.4%	+0.3%	+0.7%	+0.3%	+0.1%
Oct 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$36.14	$36.32	+0.5%	-0.4%	-1.9%	-0.4%	+0.1%	+0.6%
Jul 22	Citigroup	Maintains	Buy → Buy	—	$35.65	$35.65	+0.0%	+1.3%	+1.0%	+2.6%	+2.9%	+4.0%
Jul 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$35.87	$36.00	+0.4%	+0.7%	-0.1%	+1.0%	+1.8%	-0.8%
Oct 25	Citigroup	Maintains	Buy → Buy	—	$27.28	$27.35	+0.3%	-1.2%	-0.1%	-0.5%	-0.3%	-1.0%
Aug 14	Goldman Sachs	Maintains	Buy → Buy	—	$26.86	$26.81	-0.2%	-0.8%	+2.0%	+1.2%	+2.3%	+1.5%
Jul 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$25.73	$25.96	+0.9%	+3.9%	+4.0%	+3.6%	+7.6%	+9.2%
Jun 3	UBS	Downgrade	Buy → Neutral	—	$27.41	$27.10	-1.1%	-2.1%	-1.4%	-1.5%	-1.2%	+0.2%
Apr 12	BofA Securities	Maintains	Buy → Buy	—	$29.05	$29.06	+0.0%	-2.9%	-2.8%	-5.5%	-5.0%	-4.0%
Feb 20	Goldman Sachs	Maintains	Buy → Buy	—	$29.92	$29.91	-0.0%	+1.3%	+4.4%	+3.7%	+3.7%	+4.7%
Feb 20	JP Morgan	Maintains	Overweight → Overweight	—	$29.92	$29.91	-0.0%	+1.3%	+4.4%	+3.7%	+3.7%	+4.7%
Nov 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$27.62	$27.87	+0.9%	-0.8%	-1.4%	-1.8%	-0.4%	-2.2%
Oct 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$26.93	$26.95	+0.1%	+0.8%	+0.6%	+3.4%	+3.8%	+5.8%
Aug 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$30.55	$30.72	+0.6%	+0.0%	+0.1%	-0.3%	-1.4%	-2.5%
Jul 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$30.05	$30.26	+0.7%	+2.2%	+4.1%	+2.2%	+2.3%	+2.0%
May 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$33.99	$33.96	-0.1%	-0.4%	+1.5%	+1.6%	+1.0%	-2.2%
Apr 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$36.38	$36.58	+0.5%	-0.2%	+0.4%	-0.7%	+0.4%	-0.3%
Apr 6	Tigress Financial	Maintains	Buy → Buy	—	$36.27	$36.43	+0.4%	+0.3%	+0.1%	+0.7%	-0.4%	+0.7%
Feb 16	UBS	Maintains	Buy → Buy	—	$37.69	$37.53	-0.4%	-1.2%	+0.4%	-1.1%	-1.5%	-1.5%
Dec 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$43.01	$42.85	-0.4%	-2.5%	-2.0%	-1.6%	-2.9%	-1.9%
Nov 9	Morgan Stanley	Maintains	Overweight → Overweight	—	$42.69	$42.82	+0.3%	+0.8%	+3.0%	+2.9%	-0.4%	-1.4%
Oct 18	JP Morgan	Maintains	Overweight → Overweight	—	$41.78	$42.21	+1.0%	+0.6%	-1.8%	-2.2%	-1.8%	-1.2%
Sep 13	Scotiabank	Maintains	Outperform → Outperform	—	$43.64	$43.04	-1.4%	-2.4%	-2.7%	-3.4%	-3.9%	-4.6%
Aug 8	Morgan Stanley	Maintains	Overweight → Overweight	—	$42.45	$42.60	+0.4%	+1.6%	+2.9%	+3.5%	+2.9%	+4.1%
Jul 14	Tigress Financial	Maintains	Buy → Buy	—	$42.39	$42.33	-0.1%	+1.9%	+3.6%	+3.1%	+3.0%	+1.5%
Jun 14	UBS	Maintains	Buy → Buy	—	$38.46	$38.34	-0.3%	-0.7%	+0.2%	-0.4%	+2.3%	+4.3%
May 13	Scotiabank	Maintains	Outperform → Outperform	—	$38.95	$40.00	+2.7%	+2.5%	+3.4%	+6.2%	+4.0%	+2.1%
Apr 27	Goldman Sachs	Maintains	Buy → Buy	—	$41.83	$42.19	+0.9%	+2.8%	+4.1%	+1.8%	+1.2%	+2.1%
Apr 14	JP Morgan	Upgrade	Neutral → Overweight	—	$42.44	$43.18	+1.7%	+3.9%	+3.9%	+4.1%	+4.2%	+2.7%
Apr 6	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$39.84	$39.92	+0.2%	+1.4%	+2.5%	+4.0%	+4.2%	+4.9%
Oct 29	Citigroup	Upgrade	Neutral → Buy	—	$38.20	$39.10	+2.4%	+3.5%	+4.0%	-0.2%	+3.4%	+3.6%
Aug 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$38.73	$38.67	-0.2%	-1.2%	+0.9%	-0.0%	+0.4%	+0.7%
Jul 30	Tigress Financial	Maintains	Buy → Buy	—	$38.25	$38.32	+0.2%	-0.1%	-2.7%	-1.5%	-3.9%	-2.6%
Nov 9	UBS	Upgrade	Neutral → Buy	—	$40.24	$42.86	+6.5%	+1.8%	+0.9%	+0.2%	+1.0%	+4.7%
Jul 13	JP Morgan	Maintains	Neutral → Neutral	—	$47.64	$47.20	-0.9%	-7.5%	-8.6%	-9.7%	-11.4%	-7.2%
Jul 13	BofA Securities	Maintains	Buy → Buy	—	$47.64	$47.20	-0.9%	-7.5%	-8.6%	-9.7%	-11.4%	-7.2%
Jul 13	Cowen & Co.	Maintains	Outperform → Outperform	—	$47.64	$47.20	-0.9%	-7.5%	-8.6%	-9.7%	-11.4%	-7.2%
Jul 13	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$47.64	$47.20	-0.9%	-7.5%	-8.6%	-9.7%	-11.4%	-7.2%
Jul 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$47.64	$47.20	-0.9%	-7.5%	-8.6%	-9.7%	-11.4%	-7.2%

Recent Filings

8-K

Unknown — 8-K Filing

Revolution Medicines secured up to $1 billion in non-dilutive financing tied to daraxonrasib's FDA approval milestones, reducing capital needs while Royalty Pharma gains royalty upside if the drug achieves blockbuster sales.

Apr 13

8-K

Royalty Pharma plc Class A -- 8-K Filing

Royalty Pharma delivered strong 2025 performance with 16% portfolio receipt growth, record shareholder returns, and $2.6 billion in new royalty investments, demonstrating robust cash generation and strategic capital deployment.

Feb 11

Data updated apr 26, 2026 11:29pm · Source: massive.com